Core Viewpoint - China Zhongfu (01763) anticipates a decline in revenue and net profit for the fiscal year ending December 31, 2025, compared to the same period in 2024, primarily due to decreased earnings from its nuclear medical equipment division and tax-related expenses from a subsidiary [1] Financial Performance - Revenue is expected to be approximately RMB 6.979 billion to RMB 7.206 billion, representing a year-on-year decrease of about 5% to 8% [1] - Net profit is projected to be around RMB 611 million to RMB 655 million, reflecting a year-on-year decline of approximately 25% to 30% [1] - Profit attributable to equity shareholders is estimated to be between RMB 302 million and RMB 322 million, indicating a year-on-year reduction of about 20% to 25% [1] Operational Status - The company's operations are currently running normally, despite the anticipated revenue and profit declines [1]

Core Viewpoint - COFCO Joycome (01610) anticipates a loss attributable to shareholders of approximately RMB 230 million to RMB 350 million for the fiscal year 2025, compared to a profit of approximately RMB 259 million in the same period last year [1] Group 1: Financial Performance - The company's adjusted performance has shifted from profit to loss primarily due to a significant year-on-year decline in pig sales prices, which have remained at low levels [1] - Despite improvements in breeding costs and notable breakthroughs in fresh brand business, the overall profitability has decreased year-on-year [1] Group 2: Business Operations - The pressure on profit margins in the breeding business has been a key factor in the decline of overall earnings [1] - The effectiveness of technology-driven initiatives has been observed, contributing positively to certain aspects of the business [1]

Core Viewpoint - China Traditional Chinese Medicine (0570.HK) experienced a decline of 4.57%, closing at HKD 2.09, with a trading volume of HKD 95.08 million and a market capitalization of HKD 10.5 billion. The company announced a projected loss for the fiscal year ending December 31, 2025, marking a significant shift from profit to loss, with expected losses between RMB 350 million to RMB 500 million, compared to a profit of RMB 20.77 million in the previous year. Adjusted net profit is anticipated to decrease by 45% to 55%, down from RMB 636 million in the prior year [1][1][1] Financial Performance - The company expects to report a loss for the fiscal year 2025, which would be the first loss since 2013 [1] - The adjusted net profit is projected to decline by 45% to 55%, with the previous year's figure being approximately RMB 636 million [1] Analyst Ratings - Morgan Stanley has updated its risk-reward rating for China Traditional Chinese Medicine, lowering earnings forecasts for 2026 to 2030 by 5% to 12% and reducing the target price from HKD 1.5 to HKD 1.4, maintaining a "Reduce" rating [1][1] - The firm believes there is a 70% to 80% probability that the stock price will decline over the next 30 days, primarily due to the profit warning [1][1] Market Outlook - The company faces challenges due to a shrinking market size, and it has not disclosed specific plans for market expansion through internal resources or acquisitions [1] - The market currently has low visibility regarding the company's performance in 2026, indicating further potential downside for the stock price [1]

Core Viewpoint - China Port Energy (00931) has experienced a significant decline of nearly 14%, currently trading at 0.475 HKD, with a transaction volume of 63.48 million HKD. The company anticipates a loss attributable to shareholders of approximately 65 million to 75 million HKD for the six months ending September 30, 2025, compared to a loss of about 54 million HKD for the corresponding period ending September 30, 2024. This change is primarily due to an asset disposal of around 13 million HKD during the current interim period [1]. Financial Performance - The company expects a loss of approximately 65 million to 75 million HKD for the six months ending September 30, 2025 [1] - For the corresponding period ending September 30, 2024, the anticipated loss is about 54 million HKD [1] - The asset disposal during the current interim period amounts to approximately 13 million HKD [1] Business Operations - The period from April to September is identified as the off-peak season for the company's liquefied natural gas business and the largest segment of its new energy business providing heating services in northern China [1] - The company has several new projects planned for launch in the second half of the year, which are expected to contribute positively to revenue and profitability [1] - The board expresses optimism regarding the company's transition from a loss to profit for the fiscal year ending March 31, 2026, based on current business activities and development trends [1]